Alzheimer’s disease’s first in vitro diagnostic test was granted to Breakthrough Device Designation. The U.S. Food and Drug Administration approved its marketing. The amyloid plaques early detection diagnostic test called Lumipulse G β-Amyloid Ratio (1-42/1-40) is ideal for patients aged 55 years and older displaying cognitive impairment and other causalities of cognitive decline. Dr. Jeff […]
The post Alzheimer’s Disease Diagnostic Test Approved for Marketing by FDA appeared first on Guardian Liberty Voice.